Rituximab-induced interstitial lung disease

Discussion:

Rituximab pneumonitis is a rare side effect of the CD20 monoclonal antibody rituximab. It is used for oncological/hematological and rheumatological disorders.

Before the rituximab therapy, there is no evidence of interstitial lung disease. Two months later from the rituximab therapy HRCT shows new developing interstitial lung disease, presumably related to rituximab. There were no other etiological factors for interstitial lung disease or radiotherapy history. 

It is suggested that if any patient while receiving "rituximab" presents with dyspnea, persistent fever and cough or new radiographic findings this diagnosis should be considered.

    Create a new playlist
Loading...